France has launched a public consultation about cannabis legalization asking citizens about their views on cannabis and what government policies people would prefer, France24 reports.
Articles
Top Penny Stocks To Watch For 2021 If You’re Following Mushroom Stocks
Whether you’ve traded for decades or just opened an account, the market attracts you for a reason.
CYBIN Announces Upsize to Previously Announced Bought Deal Offering
Cybin's bought deal financing has been upsized to CAD$30 million.
Low Tide For Psychedelic Stocks With Media, Investors Distracted
The U.S. election has become a major political circus. With investors distracted and the media focused elsewhere, psychedelic stocks are temporarily at low tide.
Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development
Entheon announces a new partnership to advance its psychedelic drug R&D.
Cybin Announces CDN$20 Million Bought Deal Offering
Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
Psychedelic Schools for ‘Shamans’ Are Popping Up Like Mushrooms
Even before Oregon and Washington, D.C., decriminalized medical psilocybin, the active ingredient in “magic mushrooms,” in November, a market was emerging for schools that teach mental and medical health professionals how to use psychedelics in their treatment.
What Will The Psychedelics Space Look Like In 2021? Experts Weigh In
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.
The public’s perception of the harms of magic mushrooms is in line with science — but not with the law
New research suggests that the public’s perception of the potential harms of magic mushrooms is not in line with drug laws.
Despite Losses, Canadian Cannabis CEOs Among Nation’s Highest-Paid Executives
Several Canadian cannabis company CEOs were among the highest paid corporate executives in the nation in 2019, according to a Centre for Policy Alternatives’ analysis titled “The Golden Cushion: CEO compensation in Canada.”
Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO
LONDON — ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
Feds To Send Marijuana And Hemp Samples To Labs As Part Of Large-Scale Testing Accuracy Study
A federal science agency is inviting labs to participate in a large-scale study to assess their ability to accurately analyze marijuana and hemp samples for their cannabinoid profile and possible contaminants.
Local Massachusetts Lawmakers Unanimously Approve Psychedelics Decriminalization Measure
Local Massachusetts lawmakers on Thursday unanimously approved a resolution to decriminalize a wide range of psychedelics—the latest in a national movement to reform laws on entheogenic plants and fungi.
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.